Abstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox ® ) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfl uoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affi nity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fl uids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gramnegative ocular pathogens.
Introduction
Moxifl oxacin hydrochloride ophthalmic solution 0.5% is the ocular formulation/adaptation of moxifl oxacin, an 8-methoxyfl uoroquinolone, broad spectrum, anti-infective. It was introduced in 2003 as Vigamox ® (Alcon Laboratories, Inc, Fort Worth, TX, USA) for the treatment of susceptible microorganisms recovered from patients with bacterial conjunctivitis. It is used more frequently off label for treatment of keratitis and as a prophylaxis agent in cataract and refractive surgeries (Vigamox 2004; Alfonso and Crider 2005; Schlech and Alfonso 2005) .
It is an isotonic, preservative free, solution with a near neutral pH of 6.8. The formula of Vigamox includes 5 mg/mL (0.5%) of moxifl oxacin, boric acid, and purifi ed water. Lack of the preservative BAK (benzalkonium chloride) makes it unique among current topical antibiotics licensed for use. Vigamox is currently available in more than 40 countries. Moxifl oxacin hydrochloride ophthalmic solution 0.5%, under the trade name Vegamox ® , was introduced into Japan in 2006, with approval for the treatment of bacterial conjunctivitis, keratitis and surgical prophylaxis. Figure 1 shows the basic molecule and Figure 2 the moxifl oxacin molecule. Table 1 shows the impact of core modifi cations.
Chemistry

Moxifl oxacin
Moxifl oxacin is a broad spectrum, 8-methoxy fl uoroquinolone with improved activity against Streptococci and Staphylococci and moderate to excellent activity against clinically relevant, gram negative ocular pathogens (Smith et al 2001; Keating and Scott 2004) .
Miller
Modifi cation of the parent molecule's core 4-quinolone core, at positions 1, 5, 7, and 8 has engineered novel fl uoroquinolones with enhanced antimicrobial activity, safety and tolerability (Keating and Scott 2004) . Substitutions at the N-1 nitrogen atoms are critical for the spectrum of activity and potency of the molecule. The N-1 cyclopropyl substitution in moxifl oxacin confers increased activity against gram-positive and anaerobic isolates. Substitutions at the C-5 position also impact the in vitro activity against gram-positive isolates; the larger the molecule the greater the gram positive potency. Addition of a bulky C-7 (diazabicyclononyl ring) side chain and a methoxy group at the C-8 position reduces the potential for selection of resistant bacterial subpopulations and increase the binding/blocking affi nity for DNA gyrase and topoisomerase IV, essential bacterial enzymes (Domagala 1994; Ball et al 1998; Appelbaum and Hunter 2000; Peterson 2001; Zhanel et al 2002; Caeiro and Iannini 2003; Saravolatz and Leggett 2003) These modifications were incorporated to meet the challenge of emerging resistance in the older fl uoroquinolones among ocular and nonocular isolates Chaudhry et al 1999; Goldstein et al 1999; Alexandrakis et al 2000; Zhanel and Noreddin 2001; Mather et al 2002; Hwang 2004; Mah 2004; Marangon et al 2004; Van Bambeke et al 2005) .
Mechanism of action
Moxifl oxacin is a bactericidal, concentration dependent, anti-infective. It interferes with bacterial survival by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. DNA gyrase is encoded by the genes gyra A and gyr B, while topoisomerase IV is encoded by Par C (grl A) and pare (grl B). Inhibition of either enzyme leads to bacteria death (Zhanel and Noreddin 2001; Hwang 2004; Mah 2004; Van Bambeke et al 2005) .
All fl uoroquinolones bind to DNA gyrase and topoisomerase enzymes in susceptible organisms. The affi nity or strength of the attachment varies; dependent on the class of fl uoroquinolone and the bacteria species. Moxifl oxacin binds strongly to both DNA gyrase and topoisomerase, but demonstrates preferential binding to DNA gyrase in gram-negative pathogens and Streptococcus pneumoniae. There is controversy as to the preferential target in the staphylococci. Preferential of dual targeting confi rmation is dependent on methods used to evaluate the targets, and wild type strains employed to generate the mutants (Hooper 2001a; Oliphant and Green 2002; Ball et al 2004; Keating and Scott 2004) .
Studies confi rmed that for the older fl uoroquinolones such as ciprofl oxacin, topoisomerase IV is the preferred target in gram positive bacteria (Ball et al 1998; Dalhoff and Schmitz 2003; Drlica and Malik 2003; Zhanel et al 2006) . In vitro studies supporting the dual activity of moxifl oxacin have been mixed. Takei and colleagues using MIC ratios; classifi ed moxifl oxacin as a class three quinolone exhibiting dual activity against the two enzymes in Staphylococcus aureus (Takei, 
Fukuda et al 2001)
. Topoisomerase IV was identifi ed as the preferential target, with purifi ed S. aureus DNA gyrase and topoisomerase IV enzymes by Ince and colleagues (Ince et al 2003) . Griggs and co-workers (Griggs et al 2003) selected mutants with preferred affi nity for DNA gyrase. Exposure to fl uoroquinolones may select single step mutants and or bacterial populations with increased tolerance or resistance. Mechanisms of resistance to the fl uoroquinolones include subpopulations (mutants) with 1) mutations in DNA gyrase and or topoisomerase genes that alter/reduce the binding affi nity of the enzymes, 2) gene mutations that block drug entry, 3) presence of an effl ux pump that reduces drug accumulation and 4) unique genes that confer specifi c resistance against S. aureus (Zhanel et al 2002; Wise 2003; Mah 2004; Jacoby 2005; Van Bambeke et al 2005) . Rare or emerging resistant mechanisms include 1) the presence of plasmids that protect cells from the lethal effects of the fl uoroquinolones and 2) acquisition of a fl uoroquinolone modifying enzyme .
Low level fl uoroquinolone resistant populations usually contain a single mutation in DNA gyrase or topoisomerase IV. The preferred or primary target varies with the bacteria species and the fl uoroquinolone. Key mutations usually occur in a unique region known as the quinolone resistant determining region (QRDR) of either DNA gyrase or topoisomerase IV. Secondary mutations may also occur in genes outside of these regions, in genes encoding effl ux pumps, membrane permeability and cell transport. High level resistant isolates contain multiple gene mutations both in primary and in secondary targets. In areas with preexisting low levels of fl uroquinolone resistance, exposure to suboptimal levels of the new fl uoroquinolones will lead to rapid progression to double mutants and high level resistance (Hooper 2001b; Smith et al 2001; Zhanel et al 2002; Hwang 2004; Miller and Alfonso 2004) . Figure 3 highlights the evolution of fl uoroquinolones resistance among ocular isolates recovered from postoperative endophthalmitis cases from one region . At base line (1990) (1991) (1992) (1993) (1994) , low level resistance to ciprofl oxacin (10.3%) was evident, with no documented resistance to levofl oxacin, gatifl oxacin, or moxifl oxacin. Emergence of multistep mutants or subpopulations resistant to levofl oxacin and the 8 methoxy fl uoroquinolones were steeper and almost 3 times higher compared to ciprofl oxacin during the initialfi ve years following ciprofl oxacin's introduction. Increasing resistance to ciprofl oxacin and levofl oxacin doubled in the last 5 years. Resistant populations increased by 8.9% for gatifl oxacin and 5.1% for moxifl oxacin during that same time period.
Spectrum of activity
In vitro studies comparing minimal inhibitory concentrations (MICs) from the United States, Asia and Europe have documented the in vitro effi cacy of moxifl oxacin against a broad array of ocular and nonocular pathogens Krasemann, Meyer et al 2001; Zhanel, Ennis et al 2002; Caeiro and Iannini 2003; Dalhoff and Schmitz 2003; Hwang 2004; Keating and Scott 2004; Mah 2004) . Emerging trends indicate enhanced activity and excellent coverage for S. pneumoniae, Haemophilus infl uenzae, and methicillin susceptibile staphylococci compared to older fl uoroquinolones. There was near equivocal coverage for Enterobacteriaceae, Pseudomonas aeruginosa, and other nonfermenters, but Table 2 . Greater than 10% resistance for moxifl oxacin and or gatifl oxacin was documented for several ocular pathogens, including S. pneumoniae (11.9%), methicillin resistant S. aureus (95% USA, 23.3% Taiwan, methicillin resistant Staphylococcus epidermidis (69% USA, 40% Taiwan) and P. aeruginosa (18.3% Taiwan).
Currently, there are few large, credible studies evaluating in vitro activity of moxifl oxacin against new and older fl uoroquinolones for common ocular pathogens. Many are hampered by low numbers of isolates (less than 30 per species), incomplete panel of challenge, comparative antibiotics or spectrum of pathogens and use confl icting or outdated interpretation standards. Table 3 compares minimal inhibitory concentrations needed to inhibit 90% of pathogens (MIC 90 s) for select ocular pathogens from North and South America for ciprofl oxacin, gatifl oxacin, and moxifl oxacin. Results are impacted by methodology, isolate mix, testing period and interpretation standard applied. Minimal inhibitory concentrations against relevant ocular pathogens indicated that the 8-methoxy fl uoroquinolones have improved effi cacy against common ocular pathogens compared to ciprofl oxacin. MIC 90 s were 2-4 times lower for moxifl oxacin versus ciprofl oxacin and lower than or equivocal to gatifl oxacin among important ocular pathogens. Percent susceptible ranged from 24% (methicillin-resistant staphylococci) to 100% (S. pneumoniae) (Mather et al 2002; Kowalski et al 2003; Kowalski et al 2005; Stroman et al 2005; Oliveira et al 2007) . Isolates resistant to ciprofl oxacin were in general also resistant to moxifl oxacin and gatifl oxacin.
Resistance patterns to the fluoroquinolones vary by region, country, and ocular site. Studies comparing endemic background ciprofloxacin resistance demonstrated wide variation across regions in Europe, and North and South America (Table 4 ). Emerging resistant rates to moxifl oxacin and gatifl oxacin correlated with background ciprofl oxacin resistant rates. Regions with the highest endemic resistance also reported the highest resistant rates to moxifl oxacin and gatifl oxacin (Mather et al 2002; Kowalski et al 2003; Kowalski et al 2005; Oliveira et al 2007) (Miller 2006, unpublished) .
Other microbial pathogens considered susceptible to moxifl oxacin include Chlamydia pneumoniae, Chlamydia Moxifl oxacin hydrochloride ophthalmic solution trachomatis, Legionella pneumoniae and the some Mycobacteria species (Vigamox 2004) .
Treatment of nontuberculosis with the 8-methoxyfl uoroquinolones has been mixed. In a review of the early literature, Abshire and colleagues (Alcon Laboratories) offered data to support the use of moxifl oxacin in the prevention and treatment on mycobacterial keratitis (Abshire et al 2004) . Several case and series report successful treatment outcomes with the 8 methoxyfl uoroquinolones as adjunctive therapy (Lee et Karp et al 2003; Winthrop et al 2003; John and Velotta 2005) . Increased awareness, control measures and modifi ed surgical techniques have reduced the frequencies of mycobacterial infections in the United States. The current recommendation for treatment of mycobacterial keratitis is alternative treatment with amikacin and one of the 8-methoxyfl uoroquinolones .
Case reports and series from other ocular sites have been rare (Gupta et al 2003; Nielsen et al 2004;  . The antifungal activities of the 8-methoxyfl uoroquinolones have been investigated. There is both in vitro and in vivo evidence for some effi cacy of the 8 methoyl fl uoroquinolones to reduce fungal loads in the lab and for patients with contact lens associated fungal keratitis. Additional studies need to be done (Ozdek et al 2006; Munir et al 2007) 
Pharmacokinetics
Direct application of topical antimicrobial to conjunctival and corneal tissues can initially provide very high local and aqueous chamber concentrations. Final or sustained concentrations are altered by rapid tear fi lm dissipation, underlying tissue health and dosing frequency (Robertson et al 2005; Stroman et al 2005) .
Penetration of moxifoxacin has been studied in ocular tissues and fl uids in both humans and animals. Human studies have revealed wide variation in drug concentrations. Recorded concentrations are impacted by route of administration, dosing frequency, site of infection, presence or absence of epithelial defect and underlying disease. The recommended dosing frequency for the treatment of bacterial conjunctivitis is one drop 3 times a day for 5 days. (Vigamox 2004; Alfonso and Crider 2005; Robertson et al 2005; Stroman et al 2005) In general, moxifl oxacin's high concentration formulation, enhanced bioavailability, and solubility have allowed for levels 2-to 4-fold higher ocular tissues levels than gatifl oxacin (Zymar Table 5 summarizes studies evaluating the penetration of moxifl oxacin, gatifl oxacin and ciprofl oxacin into the aqueous and vitreous chambers by topical and oral routes of administration. Topical dosing protocols that mimic pre and post dosing frequencies for cataract and refractive surgeries of 4 times a day, pulsing dosing or a combination of the two, report concentration levels in the aqueous chamber that ranged from 0.38 ± 0.32 μg/mL to 2.28 ± 1.23 μg/mL.
Resultant concentration in the vitreous ranged from 0.011 ± 0.008 μg/mL to 0.11 ± 0.05 μg/mL. Vitreal concentrations were 20-to 40-fold lower than those obtained in the aqueous. ( Oral administration of 400-800 mg of moxifl oxacin ranged from 0.21 ± 0.21 μg/mL to 2.33 μg/mL ± 0.85 and produced concentrations that were comparable to topical administration in the aqueous chamber. Drug levels were negligible in the vitreous 
Pharmacodynamics
The therapeutic success or potency of an antibacterial agent is a complex interrelationship between drug and its ability to reach the target site (pharmacokinetics), the microbial pathogen and susceptibility to the selective drug (pharmacodynamics), and the underlying immune status of the patient (Figure 4) . Pharmacokinetics is the dispersion and metabolism of the drug in the body. It is defi ned by the absorption, distribution, dosage and protein binding characteristics of the drug, which may vary among individual drugs in a class. Pharmacodynamics defi nes the impact of the antimicrobial agent on the infecting microorganism. It is characterized by the bacterial species, mechanism of microbial resistance, growth phase, infecting inoculum, degree of kill, time kill and MIC distribution. The third partner in this complex relationship is what both the drug and the pathogen do to the patient. This interplay is described by the patient's age, genetic background, underlying disease and prior antimicrobial exposure.
The ratio of peak concentration (C max ) to the MIC and the area under the concentration curve (AUC) are the pharmacodynamic indices that correlate most favorable with clinical outcomes for concentration-dependent anti-infectives. Maintaining adequate concentration of an antibiotic above a certain level known as the mutant prevention concentration (MPC) can also reduce the probability of selecting resistant subpopulations and increasing a favorable clinical outcome.
Antibiotic penetration into ocular tissues and fl uids must not only reach but exceed the minimal inhibitory concentration (MIC) suffi ciently to meet the targeted pharmacodynamic indices (C max : MIC or MPC) by a factor of 10. A C max :MIC ratio or MPC values greater than 10 have been documented to eradicate pathogens and suppress emergence of resistance in patients treated with fl uoroquinolones (Allen et al 2004; Metzler et al 2004; Smith et al 2004; Hermsen et al 2005) .
Wilhelmus Wilhelmus et al 2003) confi rmed the application and utility of pharmacodynamic indices to predict clinical outcome in patients with bacterial keratitis. The pharmacodynamic indices (PDI): C max :MIC and AUC:MIC were use to correlate clinical outcome for 391 patients with bacterial keratitis. Clinical improvement was associated with a C max :MIC ratio greater than 8 and an AUC:MIC ratio greater than 152. Corneal pathogens included S. aureus (21%), P. aeruginosa (12%), S. pneumoniae (7%), Streptococcus viridans (5%), other gram-positive isolates (44%), and other gram-negative isolates (11%). Table 6 displays calculated pharmacodynamic indices (PDI) for moxifl oxacin and gatifl oxacin using reported aqueous concentrations and MIC 50 s/MIC 90 s values for coagulase negative staphylococci recovered from endophthalmitis (Mather et al 2002; Miller et al 2006) Targeted PDIs ranged from less than or equal to 0.038 μg/mL to 0.228 μg/mL for moxifl oxacin and less than or equal to 0.048-0.094 μg/mL for gatifl oxacin. Obtainable moxifl oxacin concentrations exceeded the MIC and met the PDI factor of 10 for 89% (8/9) and 78% (7/9) of the isolates when using the MIC 50 . None of the moxifl oxacin concentrations were suffi cient to provide coverage for fl uoroquinolone resistant coagulase negative staphylococci for reported MIC 90 s.
Gatifl oxacin concentrations met the PDI factor of 10 for 28% (2/7) of the isolates at the MIC 50 value of 0.09 μg/mL. None of the obtainable Zymar concentrations met the PDI factor of 10 for fl uoroquinolone resistant isolates at values reported by Miller et al (2006) .
In a more recent report from the same Institution, Harper and colleagues (Harper et al 2007) confi rmed the low peak concentration:mic ratios for both gatifl oxacin and moxifl oxacin using reported intraocular levels against 59 coagulase negative staphylococci isolates collected between 1993 and 2006. Moxifl oxacin ratios (C max :MIC 90 ) were higher than gatifl oxacin (0.05 μg/mL vs 0.02 μg/mL) but lower than vancomycin (0.45 μg/mL) for reported mean (1.66 μg/mL) aqueous concentrations. A signifi cant difference in the PDI parameter was observed for moxifl oxacin when the MIC 50 rather than the MIC 90 was used. The ratio for moxifl oxacin using the MIC 50 was 2.2 μg/mL vs 0.83 μg/mL for gatifl oxacin and 0.67 μg/mL for vancomycin.
Clinical effi cacy
No clinical trials have been conducted evaluating moxifl oxacin vs. nonfl uroquinolone antibiotics for the treatment of keratitis and or endophthalmitis. In two pre-marketing, randomized, double-masked, multi-centered, controlled clinical trials to assess, safety and effi cacy of moxifl oxacin for the treatment of bacterial conjunctivitis, clinical cures were documented in 66%-69% of patients by day 4. Microbiological eradication occurred in 84%-94% of the patients. Patients were dosed 3 times a day for 4 days. Age groups ranged from 2 to 92. No adverse events were reported in this group (Alfonso and Crider 2005).
Deramo and colleagues reported no signifi cant difference in the rate of endophthalmitis using 4 times a day dosing of moxifl oxacin or gatifl oxacin pre-and post-operative compared to established endophthalmitis infection rates. In a retrospective, multicentered review of 20,013 patients from 9 cataract centers across 7 states, the overall rate of endophthalmitis following cataract surgery was 0.07%. The rate of postoperative endophthalmitis in the gatifl oxacintreated group (81%, 16,209) was 0.06% (9 cases) and the rate for the moxifl oxacin-treated group (19%, 3804) was 0.1% (5 cases). The difference was not signifi cant (p = 0.11, nor was this rate lower than the earlier study by Miller et al using clear corneal phacoemulsifi cation (Miller et al 2005; Deramo et al 2006) .
Safety and biocompatibility
Reported adverse reactions with 0.5% moxifl oxacin hydrochloride ophthalmic solution administration have included: conjunctivitis, keratitis, decreased visual acuity, ocular hyperemia, dry eye, itching, subconjunctival hemorrhage, and tearing (Alcon Laboratories package insert) . Other infrequent ocular adverse events reported for the fl uoroquinolones as a class include chemosis, eyelid edema, and punctuate epithelial keratitis (Mah 2004) .
In vitro and animals studies have demonstrated a concentration dependent toxicity in studies of corneal epithelial cell migration and or proliferation, key components in corneal wound healing (Mallari et al 2001; Donnenfeld et al 2004; Kovoor et al 2004; Burka et al 2005; Durrie and Matsumoto and colleagues reported low and equivocal cell migration inhibition scores for moxifl oxacin and gatifloxacin versus ciprofloxacin at low concentrations (Ͻ0 .4 mmol/L), but greater toxicity for moxifl oxacin and ciprofl oxacin versus gatifl oxacin at higher concentrations (Ն0.64 mmol/L) (Matsumoto et al 2006) . McDermott and Wheater correlated dilutions and effects on migration, adhesion, collagen type four expression and presence of fi bronectin of the two commercially available 8-methoxy fl uoroquinolones (moxifl oxacin and gatifl oxacin) on human corneal and conjunctival epithelial cell lines (McDermott and Wheater 2006) . Increased toxicity was again correlated with higher drug concentrations. Gatifl oxacin was reported to be less toxic than moxifloxacin at all concentrations.
Results of other in vitro studies evaluating, the toxicity of the 8-methoxyfl uoroquinolones in human and animal corneal tissues have been mixed. Stern and colleagues used several animal models to compare the cellular effects of gatifl oxacin and moxifl oxacin on the rate and quality of corneal wound healing. In general, they reported greater corneal epithelial degradation, greater inhibition of collagen IV synthesis, and increased loss of normal structure in the basal lamina (Decemet's membrane) in moxifl oxacin treated eyes (Stern et al 2006) .
In two studies from the University of Texas Southwestern Medical Center, investigators reported moxifloxacin to be less toxic to the corneal epithelium than all currently available ophthalmic fl uoroquinolones (Kovoor et al 2004) . Confocal assessment documented maintenance of corneal epithelial integrity and tight junction organization after short term intense dosing with moxifl oxacin versus gatifl oxacin. Under similar conditions, moxifl oxacin induced cell loss and breakdown of tight junctions (Ly et al 2006) .
Outcomes of human studies comparing the biocompatibility of moxifl oxacin with gatifl oxacin and or older fl uoroquinolones were also mixed. In 14 healthy volunteers, where 0.5% moxifl oxacin and 0.3% gatifl oxacin drops were randomly administered to the right or left eye at 1 minute intervals for 5 minutes, higher levels of conjunctival injection, discomfort and corneal cell drop out per high power fi eld were reported for the moxifl oxacin eyes than for the gatifl oxacin eyes. No signifi cant change in pupil size or visual acuity was recorded for the two drugs (Kaufman et al 2006) .
Walter reported two cases of severe corneal toxicity after moxifl oxacin therapy. Both patients were treated for persisted sterile corneal ulcers that worsened with intense topical dosing with moxifl oxacin, but resolved after change in therapy to corticosteroids and gatifl oxacin (Walter and Tyler 2006 ). Donaldson and coworker reported no differences in visual acuity, tear breakup time or ocular surface integrity in the moxifl oxacin treated vs. non treated eyes of healthy subjects dosed 4 times daily for 3 days. Authors concluded that moxifl oxacin was safe during the 3 day treatment period that mimicked a prophylactic dosing regimen for patients scheduled for cataract surgery (Donaldson et al 2006) .
Durrie and Trattler compared the safety and tolerability of moxifl oxacin 0.5% ophthalmic solution and gatifl oxacin 0.3% ophthalmic solution for treatment and prophylaxis in patients undergoing laser-assisted in situ keratomileusis (LASIK) and laser-assisted subepithelial keratomileusis (LASEK). No differences between the two antibiotics was documented for visual acuity pupil size, SSPK, edema, haze, day and night-time glare halos, clarity of day or night vision, or dry eye symptoms up to 1 week in LASIK patients. Moxifl oxacin and gatifl oxacin were equivalent in terms of ease of use, speed of recovery, overall vision, and overall comfort for this group of patients. No differences in corneal healing were observed after LASEK surgery (Durrie and Trattler 2005) .
Burka et al evaluated the effect of the 8 methoxyfl uoroquinolones on epithelial healing following photorefractive keratectomy (PRK). At one month follow up, the moxifl oxacin treated eyes had smaller defects and healed faster than patients treated with gatifl oxacin (Burka et al 2005) . No signifi cant differences in visual outcomes were found in the six month follow up for these patients (Burka et al 2007) .
Solomon et al compared penetration and safety of ciprofl oxacin, moxifl oxacin and gatifl oxacin in patients scheduled for cataract surgery. No clinical evidence of epithelial or intraocular toxicity was noted for any of the three drugs (Solomon et al 2005) .
In general animal, in vitro, and clinical studies indicate the ocular and systemic safety and tolerability of moxifl oxacin for the treatment of ocular infections in children (3 days to 17 years) and adults (up to age 93). Reported adverse events including conjunctivitis, keratitis and endophthalmitis have been low (McGee et al 2005; Kleinmann et al 2006) .
Emerging resistance issues
Greater than 94% of the isolates in the Endophthalmitis Vitrectomy Study were gram positive bacteria (Endophthalmitis Vitrectomy Study Group 1995; Haimann et al 1996; Han et al 1996) . There are increasing reports of grampositive pathogens recovered from post refractive surgery infections. One of the anticipated advantages of the new 8-methoxyfl uoroquinolones was the increased activity (lower MICs) against resistant gram positive cocci. What has emerged among ocular and nonocular comparative studies is that the gap in improved coverage for resistant gram positive ocular pathogens is less than optimal (Kowalski et al 2003; Mather et al 2004; Miller et al 2006; Moshirfar et al 2006; Oliveira et al 2007) .
Pong et al evaluated the in vitro effi cacy of moxifl oxacin against clinical isolates with varying degrees of resistance to ciprofl oxacin. There was a high correlation between increasing ciprofl oxacin resistant levels and resistant MICs for both ofl oxacin and moxifl oxacin for gram positive isolates. The comparative MICs, however, were lower for moxifl oxacin than for ofl oxacin. In general moxifl oxacin MICs were 8-to 32-fold lower for gram-positive isolates and up to four fold lower for susceptible gram negative isolates than for the older fl uoroquinolones (Pong et al 1999) .
The improved activity of moxifl oxacin and gatifl oxacin against methicillin resistant S. aureus (MRSA) does not translated to in vivo effi cacy. No route of drug administration (oral, intravitreal, subconjunctival or topical) has provided concentrations that adequately cover the majority of MRSA with moderate or high level ciprofl oxacin resistance.
Kotulus and colleagues documented clinical failure in a subset of 9 patients with MRSA infections treated with moxifl oxacin or gatifl oxacin. A third of the patients improved with continued treatment with the 8-methoxyfl uoroquinolones; however, two thirds needed additional therapeutic intervention and only improved when switched to vancomycin and or other combination therapy. Patients who failed therapy were treated for an average of 4.5 days, while the third with favorable outcomes were treated more long term (18.1 days) (Kotlus et al 2006) . Others have also reported treatment failures for patients with MRSA. ( Coagulase-negative staphylococci remain the most frequent pathogen recovered from post cataract endophthalmitis. The consensus is that the origin of pathogens recovered from post cataract infections are seeded from the patient's conjunctiva. Small populations of organisms resistant to the 8 methoxyfl uoroquinolones may be presence as part of the resident conjunctiva fl ora. These may have been "selected" following exposure to older fl uoroquinolone. The high concentration and broad spectrum of the fl uoroquinolone may disrupt normal conjunctival fl ora and allow for colonization of more resistant bacterial and or more nonbacterial pathogens.
Mino de Kaspar and colleagues demonstrated a low rate of resistance (2%) among coagulase negative staphylococci in their study evaluating the normal conjunctiva fl ora of patients scheduled for anterior segment surgery (Mino de Kaspar et al 2005) .
Miller et al documented a high level fl uoroquinolone cross resistance among coagulase negative endophthalmitis isolates. Increasing resistance to ciprofl oxacin was paralleled by increasing resistance to both moxifl oxacin and gatifl oxacin. Moxifl oxacin provides coverage for 10/38, 26% and gatifl oxacin 13/38, 66% for the ciprofl oxacin-resistant isolates .
Role of moxifl oxacin in the management of ocular bacterial infections
No anti-infective provides ideal coverage for all pathogens for all infected sites. Selection of an effective anti-infective for ophthalmology is dependent on clinical effi cacy, background resistance, site of infection, and toxicity.
Moxifl oxacin hydrochloride ophthalmic solution 0.5% is a unique, preservative free, anti-infective which offers elevated tissue concentrations, broad spectrum of activity and a moderate to high rate of clinical success against common ocular pathogens. Declining effi cacy against methicillin susceptible and resistant staphylococci and pseudomonas species is a concern. Judicious use is warranted to maintain utility and reduce selection of resistant populations.
